Baxter (NYSE:BAX) said today that acquired Claris Lifesciences (BOM:533288) subsidiary Claris Injectables for $625 million. The deal is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination.
Baxter anticipates launching 7 to 9 new products annually over the next few years as a result of Claris Injectables’ R&D pipeline and manufacturing capacity. The Ahmedabod, Inda-based company’s portfolio of generics includes 11 molecules approved in the U.S. and 3 manufacturing facilities registered with the FDA.
Get the full story at our sister site, Drug Delivery Business News.
The post Baxter to put up $625m for Claris Injectables generics biz appeared first on MassDevice.
from MassDevice http://ift.tt/2hp4LUc
Cap comentari:
Publica un comentari a l'entrada